Jade Biosciences, a clinical-stage biopharmaceutical company, operates primarily under an exclusive worldwide license for BAFF-R targeting antibodies. Since its public listing via a 2025 business combination, the company has raised substantial capital through private placements, maintaining robust liquidity to fund ongoing R&D and operations. Despite deepening operating and net losses in 2025, Jade’s financial position is anchored by a sizable cash reserve projected to sustain operations into mid-2028. The imminent Phase I readout of its lead candidate, JADE101, represents a critical near-term milestone amid typical development and regulatory risks.